<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="228">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04432324</url>
  </required_header>
  <id_info>
    <org_study_id>GC2004</org_study_id>
    <secondary_id>2020-001696-32</secondary_id>
    <nct_id>NCT04432324</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19)</brief_title>
  <official_title>A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Hospitalized Subjects With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Grifols, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grifols Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if high dose Intravenous IVIG plus SMT can reduce
      the proportion of participants dying or requiring intensive care unit (ICU) admission on or
      before Day 29 or who are dependent on high flow oxygen devices or invasive mechanical
      ventilation on Day 29 versus SMT alone in hospitalized participants with COVID-19.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Dying or Requiring ICU Admission</measure>
    <time_frame>Up to Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who are Dependent on High Flow Oxygen Devices or Invasive Mechanical Ventilation</measure>
    <time_frame>Day 29</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in National Early Warning Score (NEWS)</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Clinical Response as Assessed by: NEWS ≤ 2 Maintained for 24 hours</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Hospital Discharge</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ICU Stay</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Any Oxygen Use</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Mechanical Ventilation</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Value and Mean Change from Baseline in Ordinal Scale</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Each Severity Category of the 7-point Ordinal Scale</measure>
    <time_frame>Day 15 and Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Sustained Normalization of Temperature</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Normalization of Fever</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants who Develop Acute Respiratory Distress Syndrome (ARDS)</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Time to Clinical Progression</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Intravenous Immune Globulin + Standard Medical Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the first intravenous (IV) infusion of IVIG on Day 1 up to a net dose of 2 gram per kilogram (g/kg), based upon participant's (body weight) administered in divided doses as infusions of 500 milligram per kilogram (mg/kg), based upon participant's body weight, over 4 days or 400 mg/kg, based upon participant's body weight, over 5 days. Participants will also receive all standard of care interventions while hospitalized, from Day 1 to Day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Medical Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive all standard of care interventions required throughout the participant's hospitalization, from Day 1 to Day 29</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intravenous Immune Globulin</intervention_name>
    <description>IVIG Intravenous infusion</description>
    <arm_group_label>Intravenous Immune Globulin + Standard Medical Treatment</arm_group_label>
    <other_name>Flebogamma DIF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Medical Treatment</intervention_name>
    <description>SMT</description>
    <arm_group_label>Intravenous Immune Globulin + Standard Medical Treatment</arm_group_label>
    <arm_group_label>Standard Medical Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Hospitalized male or female subject ≥ 18 years of age at time of Screening who is
             being treated for COVID-19.

          2. Has laboratory-confirmed novel coronavirus (SARS-CoV-2) infection as determined by
             qualitative Polymerase Chain Reaction (PCR) (reverse transcriptase [RT]-PCR), or other
             commercial or public health assay in any specimen during the current hospital
             admission prior to randomization.

          3. COVID-19 illness (symptoms) of any duration with radiographic infiltrates by imaging
             (Chest X-Ray, Computed tomography (CT) scan, etc.).

          4. PaO2/FIO2 ratio &gt; 300 to ≤ 400 mm Hg (ie, arterial oxygen in mm Hg divided by fraction
             inspired oxygen concentration [eg, 0.21 for room air])

          5. Any one of the following related to COVID-19: i. Ferritin &gt; 400 nanogram per
             milliliter (ng/mL), ii. Lactate dehydrogenase (LDH) &gt; 300 units per liter U/L, iii.
             D-Dimers &gt; reference range, or iv. C-reactive protein (CRP) &gt; 40 milligram per liter
             (mg/L).

          6. Subject (or a legal representative or a nearest relative or a relative by marriage, as
             appropriate) provides oral informed consent prior to initiation of any study
             procedures.

        Exclusion criteria:

          1. Subject requires invasive mechanical ventilation or ICU admission.

          2. Clinical evidence of any significant acute or chronic disease that, in the opinion of
             the investigator may place the subject at undue medical risk.

          3. The subject has had a known (documented) serious anaphylactic reaction to blood, any
             blood-derived or plasma product or commercial immunoglobulin.

          4. Subject has known (documented) hereditary fructose intolerance (HFI).

          5. A medical condition in which the infusion of additional fluid is contraindicated.

          6. Shock that is unresponsive to fluid challenge and/or multiple vasopressors and
             accompanied by multiorgan failure considered by the Principal Investigator not able to
             be reversed.

          7. Subject with known (documented) thrombotic complications to polyclonal IVIG therapy in
             the past.

          8. Subject with current or prior (within the past 1 month) myocardial infarction, stroke,
             deep vein thrombosis, or thromboembolic event.

          9. Subject with limitations of therapeutic effort (eg, 'do not resuscitate' status).

         10. Female subject who are pregnant or of child-bearing potential with a positive test for
             pregnancy blood or urine human chorionic gonadotropin (HCG)-based assay at
             Screening/Baseline.

         11. Subject participating in another interventional clinical trial with investigational
             medical product or device.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Navarro Puerto Jordi</last_name>
    <phone>+34935712200</phone>
    <email>jordi.navarro@grifols.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elsa Mondou</last_name>
    <phone>919-316-2079</phone>
    <email>elsa.mondou@grifols.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Maria Lluisa Pedro-Botet, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maria Lluisa Pedro-Botet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Benito Almirante Gragera, MD</last_name>
    </contact>
    <investigator>
      <last_name>Benito Almirante Gragera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Xavier Solanich Moreno, MD</last_name>
    </contact>
    <investigator>
      <last_name>Xavier Solanich Moreno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>CP 08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Pere Domingo Pedrol, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pere Domingo Pedrol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Javier Alberto Carbone Campoverde, MD</last_name>
    </contact>
    <investigator>
      <last_name>Javier Alberto Carbone Campoverde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Vicente Estrada Perez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vicente Estrada Perez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 12, 2020</study_first_submitted>
  <study_first_submitted_qc>June 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2020</study_first_posted>
  <last_update_submitted>June 12, 2020</last_update_submitted>
  <last_update_submitted_qc>June 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronavirus Disease</keyword>
  <keyword>Severe acute respiratory syndrome coronavirus 2</keyword>
  <keyword>SARS-CoV-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

